


BDP9066

Cat. No.:	HY-111424
CAS No.:	2226507-04-4
Molecular Formula:	C ₂₀ H ₂₄ N ₆
Molecular Weight:	348.44
Target:	Ras
Pathway:	GPCR/G Protein
Storage:	Please store the product under the recommended conditions in the COA.



BIOLOGICAL ACTIVITY

Description	BDP9066 is a potent and selective myotonic dystrophy-related Cdc42-binding kinase MRCK inhibitor with an IC ₅₀ of 64 nM for MRCKβ in SCC12 cells, K _i values of 0.0136 nM and 0.0233 nM for MRCKα/β in house determinations, respectively. BDP9066 has therapeutic effect on skin cancer by reducing substrate phosphorylation.
IC₅₀ & Target	IC ₅₀ : 64 nM (MRCKβ in SCC12 cells), K _i : 0.0136 nM/0.0233 nM (MRCKα/β) ^[1] .
In Vitro	BDP9066 shows antiproliferative effects with greatest activity in hematologic cancer cells. BDP9066 inhibits MLC phosphorylation and blocks SCC12 squamous cell carcinoma motility and invasion ^[1] .
In Vivo	BDP9066 topical application significantly decreases phosphorylated MRCKα S1003 staining and tumor volumes ^[1] .

REFERENCES

[1]. Unbekandt M, et al. Discovery of Potent and Selective MRCK Inhibitors with Therapeutic Effect on Skin Cancer. *Cancer Res.* 2018 Apr 15;78(8):2096-2114.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA